Which alternative to Antinevralgic Intensiv 20 comprimate Opella is the cheapest?

Based on current offers, Antinevralgic Intensiv 20 comprimate Opella has one of the best prices in the same-INN segment. Still, check the products listed to compare strength, pharmaceutical form and pack — sometimes the real difference is per dose, not per pack.

Are these alternatives therapeutically equivalent?

Generics with the same INN have the same active substance and are assessed by the European Medicines Agency (EMA) for bioequivalence. Differences appear in the excipients (relevant for patients with specific food allergies — e.g. lactose), the brand and the manufacturer. Even so, the decision to switch rests with the doctor or pharmacist; do not change a chronic treatment without consultation.

Can I replace Antinevralgic Intensiv 20 comprimate Opella with a generic without consulting the doctor?

For OTC (over-the-counter) medicines you can ask the pharmacist for an alternative with the same INN — this is accepted practice. For prescription medicines, substitution happens either through an INN prescription (the doctor prescribes the active substance, not the brand) or with the doctor's agreement. HartaFarmacii shows alternatives for information — this is not a medical recommendation.

Cheaper alternatives to Antinevralgic Intensiv 20 comprimate Opella

In short: for Antinevralgic Intensiv 20 comprimate Opella we have not yet identified equivalent medicines with the same INN in the HartaFarmacii database; the product's reference price is 22.09 RON. For a suitable therapeutic alternative, ask the doctor or pharmacist — the lists on this page are for information only, not a medical recommendation.

Here you will find comparable alternatives to Antinevralgic Intensiv 20 comprimate Opella — both same-INN generics and products from the same therapeutic category. Reference price for Antinevralgic Intensiv 20 comprimate Opella: 22.09 RON.

Generic vs original — in short

Generics contain the same active substance (INN) as the original product, at the same dose and in the same pharmaceutical form. To be authorised they must demonstrate bioequivalence — that is, a similar pharmacokinetic profile (the blood concentration over time is within ±20%). Typical differences are in the excipients (relevant for patients allergic to lactose, gluten or colourings), the brand and the manufacturer. For chronic treatments, switching from one generic to another is done with the doctor's agreement — even if the active substance is identical, individual tolerance can differ.

Frequently asked questions

Which alternative to Antinevralgic Intensiv 20 comprimate Opella is the cheapest?

Based on current offers, Antinevralgic Intensiv 20 comprimate Opella has one of the best prices in the same-INN segment. Still, check the products listed to compare strength, pharmaceutical form and pack — sometimes the real difference is per dose, not per pack.
Are these alternatives therapeutically equivalent?

Generics with the same INN have the same active substance and are assessed by the European Medicines Agency (EMA) for bioequivalence. Differences appear in the excipients (relevant for patients with specific food allergies — e.g. lactose), the brand and the manufacturer. Even so, the decision to switch rests with the doctor or pharmacist; do not change a chronic treatment without consultation.
Can I replace Antinevralgic Intensiv 20 comprimate Opella with a generic without consulting the doctor?

For OTC (over-the-counter) medicines you can ask the pharmacist for an alternative with the same INN — this is accepted practice. For prescription medicines, substitution happens either through an INN prescription (the doctor prescribes the active substance, not the brand) or with the doctor's agreement. HartaFarmacii shows alternatives for information — this is not a medical recommendation.

The lists of alternatives are built automatically from the INN field and the therapeutic category in our database — they are NOT a medical recommendation. For therapeutic substitution, consult the doctor or pharmacist. See the methodology and the editorial team.